RayKnowChina Research Map
Shortlist

BeijingCapital Medical University

Beijing Friendship Hospital

首都医科大学附属北京友谊医院

Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Beijing Friendship Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led
  2. Hepatocellular carcinoma肝细胞癌51 papers led1 open trial led
  3. Stomach cancer胃癌45 papers led7 open trials led
  4. Hepatoblastoma肝母细胞瘤1 paper led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Osteosarcoma骨肉瘤2 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  8. Neuroblastoma神经母细胞瘤47 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤1 paper led
  11. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症52 papers led3 open trials led
  12. Haemophilia A血友病 A0 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  14. IgG4-related diseaseIgG4相关性疾病12 papers led
  15. Myasthenia gravis重症肌无力1 paper led
  16. Wilson disease肝豆状核变性(Wilson 病)4 papers led1 open trial led
  17. Biliary atresia胆道闭锁4 papers led
  18. Takayasu arteritis大动脉炎2 papers led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  20. Pompe disease庞贝病1 paper led
  21. Behçet disease白塞病1 paper led
  22. IgA nephropathyIgA 肾病0 papers led
  23. Gaucher disease戈谢病2 papers led
  24. Primary biliary cholangitis原发性胆汁性胆管炎12 papers led1 open trial led
  25. Primary sclerosing cholangitis原发性硬化性胆管炎4 papers led
  26. Hirschsprung disease先天性巨结肠0 papers led

Not listed for: Nasopharyngeal carcinoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 2220232024: 1120242025: 222025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyImaging & AIMolecular markers & genomics
Departments in papersGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led12
  1. Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review.2025Biochimica et biophysica acta. Reviews on cancer
  2. Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.2025Scientific reportsFree full text
  3. Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells.2024The journal of gene medicine
  4. Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.2023BMC cancerFree full text
  5. Endoscopic Submucosal Dissection for Hypervascularized Esophageal Squamous Cell Carcinoma in Decompensated Cirrhosis With Esophageal Varices and Scars.2023The American journal of gastroenterologyFree full text
  6. Expression and Significance of N-myc downstream regulated gene 2 in the process of Esophageal Squamous Cell Carcinogenesis.2022BioengineeredFree full text
  7. Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.2022Cancer medicineFree full text
  8. Porphyromonas gingivalis secretion leads to dysplasia of normal esophageal epithelial cells via the Sonic hedgehog pathway.2022Frontiers in cellular and infection microbiologyFree full text
  9. Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination.2022Molecular cancer research : MCR
  10. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.2021Annals of palliative medicine
  11. Comorbid early esophageal cancer and Gongylonema pulchrum infection: a case report.2021BMC gastroenterologyFree full text
  12. Lysophosphatidic acid mediated PI3K/Akt activation contributed to esophageal squamous cell cancer progression.2021Carcinogenesis
All its trials on ClinicalTrials.gov, any status8
  1. Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea PolyphenolsStatus unknownNCT01496521Lead sponsorPhase 3Start 2012-01
  2. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  3. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  5. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsStatus unknownNCT04170257Study siteN/AStart 2019-10
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  7. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  8. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)2
  1. Data from Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination2023Venue not listedother
  2. Data from Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination2023Venue not listedother

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 51 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
51
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 151520222023: 9920232024: 111120242025: 882025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07780357

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  2. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  3. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionHepatitis B & cirrhosisRecurrence & prognosis
Departments in papersRadiology / nuclear medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Clinical trials / research unit
Papers it led51
  1. Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.2026Alimentary pharmacology & therapeuticsFree full text
  2. Role of the nucleotide excision repair function of CETN2 in the inhibition of the sensitivity of hepatocellular carcinoma cells to oxaliplatin.2025Carcinogenesis
  3. Predicting Treatment Response to Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients using a Deep Learning-based Approach.2025Current medical imagingFree full text
  4. Novel immune-related prognostic models for patients with hepatocellular carcinoma after curative resection.2025Hepatology international
  5. Stage-Specific Transcriptome Landscape of Hepatocellular Carcinoma: Insights From Super and Poor Survivors With Prognostic Signature Identification.2025Journal of digestive diseases
  6. Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography.2025Molecular pharmaceutics
  7. Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.2025Oncogene
  8. Deep learning for hepatocellular carcinoma recurrence before and after liver transplantation: a multicenter cohort study.2025Scientific reportsFree full text
  9. Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.2025The oncologistRCTFree full text
  10. Preoperative prediction power of radiomics and non-radiomics methods based on MRI for early recurrence in hepatocellular carcinoma: a systemic review and meta-analysis.2024Abdominal radiology (New York)
  11. Deep learning-based arterial subtraction images improve the detection of LR-TR algorithm for viable HCC on extracellular agents-enhanced MRI.2024Abdominal radiology (New York)
  12. The timing phase affected the inconsistency of APHE subtypes of liver observations in patients at risk for HCC on the multi-hepatic arterial phase imaging.2024Abdominal radiology (New York)
  13. The Diagnostic Accuracy Between Radiomics Model and Non-radiomics Model for Preoperative of Microvascular Invasion of Solitary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2024Academic radiology
  14. Inter-reader agreement of LI-RADS treatment response algorithm among three readers with different seniorities for hepatocellular carcinoma after locoregional therapy.2024Acta radiologica (Stockholm, Sweden : 1987)
  15. Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.2024BMC gastroenterologyFree full text
  16. Preoperative evaluation of microvascular invasion in hepatocellular carcinoma with a radiological feature-based nomogram: a bi-centre study.2024BMC medical imagingFree full text
  17. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.2024Critical reviews in oncology/hematology
  18. Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study.2024International immunopharmacology
  19. Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.2024Journal of medical virology
  20. Ablative Treatments and Surgery for Early-Stage Hepatocellular Carcinoma: A Network Meta-Analysis.2024The Journal of surgical research
  21. MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.2023BMC medical imagingFree full text
  22. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.2023Clinical and molecular hepatologyFree full text
  23. The clinical management of hepatocellular carcinoma in China: Progress and challenges.2023Clinical and molecular hepatologyFree full text
  24. Comparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation.2023Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  25. The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.2023Frontiers in immunologyFree full text
  26. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding.2023Hepatology international
  27. Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis.2023Hepatology international
  28. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis.2023Scandinavian journal of gastroenterology
  29. Platelet membrane-derived microparticles may be biomarkers in patients with hepatocellular carcinoma and can promote the invasion and metastasis of hepatoma carcinoma cells.2023Transfusion
  30. Histological assessment based on liver biopsy: the value and challenges in NASH drug development.2022Acta pharmacologica SinicaFree full text
  31. Diagnostic performance of imaging features in the HBP of gadoxetate disodium-enhanced MRI for microvascular invasion in hepatocellular carcinoma: a meta-analysis.2022Acta radiologica (Stockholm, Sweden : 1987)
  32. High-throughput circular RNA sequencing reveals the profiles of circular RNA in non-cirrhotic hepatocellular carcinoma.2022BMC cancerFree full text
  33. Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.2022BMC medical imagingFree full text
  34. CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: a preliminary retrospective study.2022European journal of medical researchFree full text
  35. Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease.2022Hepatology international
  36. Roles of small extracellular vesicles in the development, diagnosis and possible treatment strategies for hepatocellular carcinoma (Review).2022International journal of oncologyFree full text
  37. Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: An updated meta-analysis and systematic review.2022International journal of surgery (London, England)
  38. Predictive value of hepatic venous pressure gradient and efficacy and significance of early PTVE for gastrointestinal bleeding after TACE for liver cancer.2022Journal of cancer research and therapeuticsRCT
  39. Predictors of mid-term survival after liver transplantation in patients with NAFLD cirrhosis.2022Liver international : official journal of the International Association for the Study of the Liver
  40. Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram.2022MedicineFree full text
  41. Downregulation of HULC Induces Ferroptosis in Hepatocellular Carcinoma via Targeting of the miR-3200-5p/ATF4 Axis.2022Oxidative medicine and cellular longevityFree full text
  42. Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  43. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.2022The American journal of gastroenterology
  44. Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability.2022Tissue & cell
  45. Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma.2021Cell adhesion & migrationFree full text
  46. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.2021Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  47. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis.2021Hepatology internationalRCT
  48. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.2021Hepatology international
  49. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?2021Journal of magnetic resonance imaging : JMRI
  50. Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.2021MedicineFree full text
  51. Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma.2021OncoimmunologyFree full text
Chinese-language papers (not in the count)5
  1. [Application and prospects of magnetic resonance imaging techniques in the diagnosis and evaluation of hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Construction of a stable centromere protein F overexpression cell model of hepatocellular carcinoma using CRISPR activation system].2023Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  3. [Expression and Clinical Significance of ATP Citrate Lyase in Hepatocellular Carcinoma].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  4. [Low-level viremia-induced liver fibrosis and hepatocellular carcinoma in chronic hepatitis B].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status5
  1. HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis BNot yet recruitingNCT07780357Lead sponsorStart 2026-08
  2. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  4. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  5. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 45 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
45
2021–2025
Trials led
16
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 5520212022: 6620222023: 141420232024: 9920242025: 10102025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07441850

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  2. Recruiting
    Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07747688

    Age 18 years to 90 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  3. Recruiting
    Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07835087

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  4. Recruiting
    Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07315854

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  5. Recruiting
    Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT07353684

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  6. Recruiting
    Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06788548

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  7. Recruiting
    Validating a Medical AI Fine-Tuning Platform for Major Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07795645

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  8. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  9. Recruiting
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07700979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  10. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  11. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicine
Papers it led45
  1. Comparison on the reflux and nutritional status of different reconstruction methods after laparoscopic proximal gastrectomy: a systematic review and network meta-analysis.2026Updates in surgeryFree full text
  2. Clinicopathological characteristics of 30 cases of pyloric gland adenoma: a single center case series.2025BMC gastroenterologyFree full text
  3. Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.2025Cancer letters
  4. Fusobacterium nucleatum drives gastric cancer metastasis via Gbp-CypA-NF-κB-mediated CXCL8 crosstalk between tumor cells and mast cells.2025Cell communication and signaling : CCSFree full text
  5. Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE.2025Cell death & diseaseFree full text
  6. Functions and Clinical Applications of Exosomes in Gastric Cancer.2025International journal of biological sciencesFree full text
  7. Generation of surgical reports for lymph node dissection during laparoscopic gastric cancer surgery based on artificial intelligence.2025International journal of computer assisted radiology and surgery
  8. Efficient Metabolomics Profiling from Plasma Extracellular Vesicles Enables Accurate Diagnosis of Early Gastric Cancer.2025Journal of the American Chemical Society
  9. Prognostic implications of the interaction between intratumoral microbiome and immune response in gastric cancer.2025Microbiology spectrumFree full text
  10. Incidental Finding of a Primary Polypoid Low-Grade B-Cell Gastric Lymphoma Managed with Chemotherapy.2025The American journal of case reportsFree full text
  11. Development and validation of a nomogram incorporating dietary factors for predicting Helicobacter pylori-negative early gastric cancer risk.2025World journal of gastroenterologyFree full text
  12. Clinicopathologic and endoscopic characteristics of ten patients with gastric hamartomatous inverted polyp: a single center case series.2024BMC gastroenterologyFree full text
  13. Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer.2024Chinese medical journalFree full text
  14. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis.2024Critical reviews in oncology/hematology
  15. Risk factors and a nomogram for predicting local recurrence in adult patients with early gastric cancer after endoscopic submucosal dissection.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. Investigating biomechanical alterations and emptying patterns after various gastrojejunostomy strategy.2024Food research international (Ottawa, Ont.)
  17. A nomogram for predicting survival based on hemoglobin A1c and circulating tumor cells in advanced gastric cancer patients receiving immunotherapy.2024International immunopharmacology
  18. Artificial intelligence for automatic surgical phase recognition of laparoscopic gastrectomy in gastric cancer.2024International journal of computer assisted radiology and surgery
  19. Assessment of risk factors of lymph node metastasis and prognosis of Siewert II/III adenocarcinoma of esophagogastric junction: A retrospective study.2024MedicineFree full text
  20. Helicobacter pylori promotes gastric fibroblast proliferation and migration by expulsing exosomal miR-124-3p.2024Microbes and infection
  21. LncRNA CASC19 promotes gastric cancer progression through preventing CREB1 protein ubiquitin/proteasome-dependent degradation.2023Carcinogenesis
  22. LncRNA CASC19: a novel oncogene involved in human cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  23. Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer.2023Clinical and experimental medicine
  24. Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases.2023European journal of medical researchFree full text
  25. TRIM28 suppresses cancer stem-like characteristics in gastric cancer cells through Wnt/β-catenin signaling pathways.2023Experimental biology and medicine (Maywood, N.J.)Free full text
  26. Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  27. Predictive performance of radiomics for peritoneal metastasis in patients with gastric cancer: a meta-analysis and radiomics quality assessment.2023Journal of cancer research and clinical oncologyFree full text
  28. Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion.2023Journal of cancer research and clinical oncologyFree full text
  29. Safety and efficacy of augmented-rectangle technique versus delta-shaped anastomosis for treating gastric cancer in total laparoscopic distal gastrectomy.2023Langenbeck's archives of surgery
  30. Safety and efficacy of laparoscopic proximal gastrectomy with SOFY versus laparoscopic total gastrectomy with Roux-en-Y for treating cT1-2 Siewert II/III adenocarcinoma of the esophagogastric junction: a single-center prospective cohort stu2023Langenbeck's archives of surgery
  31. Circulating Tumor Cells as Diagnostic Markers of Early Gastric Cancer and Gastric Precancerous Lesions.2023Oncology
  32. Endoscopic and clinicopathologic features of early gastric signet ring cell carcinoma ≤20 mm: a retrospective observational study.2023Scandinavian journal of gastroenterology
  33. Comparison of endoscopic submucosal dissection outcomes between early gastric cardiac and non-cardiac cancers: a retrospective single-center study.2023Scandinavian journal of gastroenterology
  34. Autoimmune gastritis with a gastric hamartomatous inverted polyp and two hyperplastic polyps: a case report.2023The Journal of international medical researchFree full text
  35. External validation of the BEST-J score and a new risk prediction model for ESD delayed bleeding in patients with early gastric cancer.2022BMC gastroenterologyFree full text
  36. MiR-1298-5p level downregulation induced by Helicobacter pylori infection inhibits autophagy and promotes gastric cancer development by targeting MAP2K6.2022Cellular signalling
  37. Deep biopsy via endoscopic submucosal dissection for primary gastric amyloidosis.2022Endoscopy
  38. Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.2022Frontiers in immunologyFree full text
  39. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis: a retrospective study in a single center.2022Scandinavian journal of gastroenterology
  40. Short-term outcomes of three rare cases of intramucosal Epstein-Barr virus-associated gastric cancer treated with endoscopic submucosal dissection.2022The Journal of international medical researchFree full text
  41. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.2021Annals of the New York Academy of Sciences
  42. The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer.2021GenesFree full text
  43. IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.2021Investigational new drugs
  44. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.2021Journal of cancer research and therapeutics
  45. Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin.2021Oncogene
Chinese-language papers (not in the count)3
  1. [Application research of endoscopic-laparoscopic regional gastric resection combined with sentinel lymph node basin dissection in patients with early gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Pathological features of early gastric cancer and its background mucosa after eradication of Helicobacter pylori and their implications for biopsy diagnosis].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Analysis of the clinical confusion and controversy of esophagogastric junction tumor from basic anatomy].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status25
  1. Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical DatasetRecruitingNCT07747688Lead sponsorStart 2026-05
  2. Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric CancerRecruitingNCT07835087Lead sponsorN/AStart 2026-08
  3. Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant TherapyRecruitingNCT07441850Lead sponsorN/AStart 2026-03
  4. Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRecruitingNCT07315854Lead sponsorPhase 2Start 2025-11
  5. Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingNCT07353684Lead sponsorPhase 2Start 2025-05
  6. Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)RecruitingNCT06788548Lead sponsorN/AStart 2024-02
  7. Validating a Medical AI Fine-Tuning Platform for Major DiseasesRecruitingNCT07795645Lead sponsorStart 2024-11
  8. Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers DiagnosisStatus unknownNCT06278064Lead sponsorStart 2024-02
  9. Plasma Metabolic Biomarkers for Multi-Cancer DiagnosisStatus unknownNCT06363123Lead sponsorStart 2024-03
  10. Plasma Metabolic Biomarkers for Gastric Cancer DiagnosisCompletedNCT06109805Lead sponsorStart 2023-10
  11. Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerStatus unknownNCT04258644Lead sponsorPhase 2Start 2020-03
  12. Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric CancerStatus unknownNCT04258657Lead sponsorPhase 2Start 2020-03
  13. Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric CancerStatus unknownNCT04345783Lead sponsorPhase 2Start 2018-01
  14. Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in ChinaCompletedNCT06869356Lead sponsorStart 2018-05
  15. A Study of Apatinib Combined With S1 in Patients With Advanced Gastric CancerStatus unknownNCT03271073Lead sponsorPhase 2Start 2016-02
  16. Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric CancerStatus unknownNCT02325999Lead sponsorEarly phase 1Start 2013-12
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  18. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Study sitePhase 3Start 2026-09
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  20. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  21. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  22. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  23. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  24. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  25. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Beijing for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led2
  1. Survival outcomes in small intestine tumors: The role of duodenum, jejunum, and ileum.2025International journal of cancer
  2. The Value of Computed Tomography in Differentiating Heterotopic Pancreas from Small Gastrointestinal Stromal Tumor.2024Discovery medicine
Earlier papers (2016–2020)1
  1. Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method.2019Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 47 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 4.2%.

Papers led
47
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 5520222023: 6620232024: 9920242025: 20202025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led47
  1. Solitary Humeral Metastasis in the Absence of Detectable Primary Neuroblastoma on Triple-tracer Imaging With 18F-FDG, 123I-MIBG, and 68Ga-DOTATATE.2026Clinical nuclear medicine
  2. False Positive of 123 I-MIBG Caused by Ectopic Thymic Rebound Hyperplasia in a Pediatric Neuroblastoma.2026Clinical nuclear medicine
  3. Unusual Initial Presentation of Epileptic Seizures in a Pediatric Patient With Neuroblastoma Detected by 18 F-FDG PET/CT Imaging.2026Clinical nuclear medicine
  4. 18 F-FDG PET/CT Demonstrates Left Adrenal Neuroblastoma in a Pediatric Patient With Beckwith-Wiedemann Syndrome.2026Clinical nuclear medicine
  5. 68 Ga-DOTATATE Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Pediatric Neuroblastoma.2026Clinical nuclear medicine
  6. Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission.2026European journal of nuclear medicine and molecular imaging
  7. 18F-FDG PET/CT volumetric parameter predicts prognosis for neuroblastoma with MYCN gain.2025Abdominal radiology (New York)
  8. Application of modified Curie and SIOPEN skeleton scoring systems in 18F-AlF-NOTA-octreotide PET/CT for neuroblastoma.2025Annals of nuclear medicine
  9. The baseline 18F-FDG PET/CT imaging features in pediatric patients with congenital neuroblastoma.2025BMC medical imaging
  10. The prognostic significance of semi-quantitative metabolic parameters and tumoral metabolic activity based on 123I-MIBG SPECT/CT in pretreatment neuroblastoma patients.2025Cancer imaging : the official publication of the International Cancer Imaging Society
  11. The Role of 18 F-AlF-NOTA-Octreotide PET/CT in the Evaluation of Central Nervous System Metastases in Neuroblastoma : A Preliminary Study.2025Clinical nuclear medicine
  12. Completely Negative 123 I-MIBG SPECT/CT, but Strong Positive 68 Ga-DOTATATE PET/CT of Multiple Metastases in a Neuroblastoma Patient.2025Clinical nuclear medicine
  13. Recurrent Solitary Pleural Metastasis Originating From Neuroblastoma as Demonstrated by 123I-MIBG Scan.2025Clinical nuclear medicine
  14. Pseudoprogression on 68Ga-DOTATATE PET/CT in a Pediatric Patient With Neuroblastoma.2025Clinical nuclear medicine
  15. Positive 18 F-FDG PET/CT and Negative 123 I-MIBG SPECT/CT Imaging in an Unusual Diaphragmatic Metastasis From Ganglioneuroblastoma.2025Clinical nuclear medicine
  16. Incidental Detection of Choroid Plexus Metastasis From Neuroblastoma Demonstrated by 68 Ga-DOTATATE PET/CT.2025Clinical nuclear medicine
  17. False-Positive Uptake of 123 I-MIBG in the Basal Ganglion in a Pediatric Neuroblastoma Patient.2025Clinical nuclear medicine
  18. 68 Ga-DOTATATE PET/CT Demonstrated More Lesions of Leptomeningeal Metastases Compared With 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.2025Clinical nuclear medicine
  19. Concurrent Intracranial and Spinal Dural Metastases Demonstrated by 68 Ga-DOTATATE PET/CT With Negative 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.2025Clinical nuclear medicine
  20. A False-Negative 123 I-MIBG SPECT/CT With True-Positive 68 Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177 Lu-DOTATATE Therapy.2025Clinical nuclear medicine
  21. Predictive value of multiparametric diagnostic model based on 2-[18F]-fluoro-D-glucose (2-[18F]-FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in differentiating between neuroblastoma and ganglioneurobla2025Clinical radiology
  22. Radiomics analysis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography for differentiating the histological classification of peripheral neuroblastic tumours.2025Clinical radiology
  23. A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma.2025European journal of nuclear medicine and molecular imaging
  24. GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8.2025European journal of nuclear medicine and molecular imaging
  25. Radiomics-based prediction of pathological subtypes in peripheral neuroblastic tumors using 123I-MIBG SPECT/CT imaging: an observational study.2025European journal of pediatrics
  26. Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas.2025Journal of medicinal chemistry
  27. Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an 18F-FDG PET/CT-based radiomics nomogram.2024Abdominal radiology (New York)RCT
  28. Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment 18F-FDG PET/CT of Primary Lesions for Pediatric Patients with Neuroblastoma.2024Academic radiology
  29. 18F-FDG PET/CT-Based Radiomics Nomogram for Prediction of Bone Marrow Involvement in Pediatric Neuroblastoma: A Two-Center Study.2024Academic radiology
  30. Whole-tumoral metabolic heterogeneity in 18F-FDG PET/CT is a novel prognostic marker for neuroblastoma.2024Cancer imaging : the official publication of the International Cancer Imaging Society
  31. Jaundice as a Rare Presentation of Neuroblastoma in a Pediatric Patient.2024Clinical nuclear medicine
  32. Coexistence of Langerhans Cell Histiocytosis and Ganglioneuroblastoma Revealed by 18 F-FDG PET/CT in a Pediatric Patient.2024Clinical nuclear medicine
  33. Solitary Dural Metastasis From Neuroblastoma Detected by 123 I-MIBG SPECT/CT.2024Clinical nuclear medicine
  34. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma.2024Pediatric radiology
  35. Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors.2024Pediatric radiology
  36. An Optimal Radiomics Nomogram Based on 18F-FDG PET/CT for Identifying Event-Free Survival in Pediatric Neuroblastoma.2023Academic radiology
  37. Axial Skeleton Radiomics of 18F-FDG PET/CT: Impact on Event-Free Survival Prediction in High-Risk Pediatric Neuroblastoma.2023Academic radiology
  38. Diagnostic Value of 18F-FDG PET/CT-Based Radiomics Nomogram in Bone Marrow Involvement of Pediatric Neuroblastoma.2023Academic radiology
  39. Leptomeningeal Metastasis From Neuroblastoma Revealed by 123 I-MIBG SPECT/CT.2023Clinical nuclear medicine
  40. Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.2023Journal of cancer research and clinical oncology
  41. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.2023Seminars in nuclear medicine
  42. Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma.2022BMC medical imaging
  43. The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.2022Cancer imaging : the official publication of the International Cancer Imaging Society
  44. MIBG Uptake in Pancreas as a Normal Variant.2022Clinical nuclear medicine
  45. The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients.2022Contrast media & molecular imaging
  46. An 18F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System.2022European journal of radiology
  47. Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis.2021Contrast media & molecular imaging

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 52 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 13.0%.

Papers led
52
2021–2025
Trials led
24
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 161620212022: 9920222023: 7720232024: 111120242025: 992025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Registry
    NCT07339345

    Age 14 years to 70 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  2. Not yet recruiting
    Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05988177

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  3. Not yet recruiting
    Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06131489

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  4. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis & prognosisTreatment regimensEBV & infection triggers
Departments in papersRadiology / nuclear medicineNeurologyOphthalmology / neuro-ophthalmology
Papers it led52
  1. Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.2025Annals of hematologyFree full text
  2. Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China.2025Annals of hematologyFree full text
  3. CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).2025Annals of hematologyFree full text
  4. Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study.2025Clinical and experimental rheumatology
  5. The effectiveness of etoposide-containing chemotherapy regimens in the initial treatment of Hemophagocytic Syndrome in pregnancy.2025Hematology (Amsterdam, Netherlands)
  6. Epstein-Barr virus infection plays a crucial role in triggering hemophagocytic lymphohistiocytosis in patients with X-linked inhibitor of apoptosis protein deficiency.2025Hematology (Amsterdam, Netherlands)
  7. Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.2025Leukemia & lymphoma
  8. Exploring the Complexities of Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis-Associated Acute Liver Failure.2025Pediatric transplantation
  9. Characteristics of epilepsy associated with hemophagocytic lymphohistiocytosis.2025Seizure
  10. The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease.2024Annals of hematology
  11. A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio.2024Annals of hematologyFree full text
  12. Haemophagocytic lymphohistiocytosis caused by GATA2 deficiency: a report on three patients.2024BMC infectious diseasesFree full text
  13. Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?2024Blood
  14. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells.2024Blood
  15. Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach using 18F-FDG PET/CT and nomogram integration.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  16. Etiological stratification and prognostic assessment of haemophagocytic lymphohistiocytosis by machine learning on onco-mNGS data and clinical data.2024Frontiers in immunologyFree full text
  17. The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study.2024Frontiers in immunologyFree full text
  18. Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis.2024Frontiers in immunologyFree full text
  19. Beta 2-microglobulin is an independent risk marker of acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.2024Journal of nephrologyFree full text
  20. Prognostic scoring system for pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis based on baseline characteristics: A multicenter retrospective study.2024Pediatric blood & cancerRCT
  21. Ocular Phenotypes in Patients With Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis in a Single Center Over 7 Years.2023American journal of ophthalmology
  22. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.2023Annals of medicineFree full text
  23. Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives.2023Expert opinion on biological therapy
  24. Case Report: HAVCR2 mutation-associated Hemophagocytic lymphohistiocytosis.2023Frontiers in immunologyFree full text
  25. Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.2023Journal of cancer research and clinical oncologyFree full text
  26. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.2023Journal of cancer research and clinical oncologyFree full text
  27. The diagnostic importance of multiple cytokines in adult hemophagocytic lymphohistiocytosis.2023Journal of clinical laboratory analysisFree full text
  28. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.2022Annals of hematology
  29. Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.2022Annals of hematology
  30. Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH.2022Annals of hematology
  31. Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy.2022Annals of medicineFree full text
  32. Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen.2022Frontiers in immunologyFree full text
  33. The Outcome of Induction Therapy for EBV-Related Hemophagocytic Lymphohistiocytosis: A Model for Risk Stratification.2022Frontiers in immunologyFree full text
  34. Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.2022Hematological oncology
  35. A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.2022Journal of healthcare engineeringFree full text
  36. Development and Validation of 18F-FDG PET/CT-Based Multivariable Clinical Prediction Models for the Identification of Malignancy-Associated Hemophagocytic Lymphohistiocytosis.2022Korean journal of radiologyFree full text
  37. Prognosis predicting value of semiquantitative parameters of visceral adipose tissue and subcutaneous adipose tissue of 18F-FDG PET/CT in newly diagnosed secondary hemophagocytic lymphohistiocytosis.2021Annals of nuclear medicine
  38. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.2021British journal of haematology
  39. Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.2021Cancer biology & therapyFree full text
  40. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.2021Cell transplantationFree full text
  41. Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib.2021Chinese medical journalFree full text
  42. Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.2021Chinese medical journalFree full text
  43. Multiple-Organ Involvement in Familial Hemophagocytic Lymphohistiocytosis Type 2 Shown on FDG PET/CT.2021Clinical nuclear medicine
  44. Clinical and laboratory signs of haemophagocytic lymphohistiocytosis associated with pandemic influenza A (H1N1) infection in patients needing extracorporeal membrane oxygenation: A retrospective observational study.2021European journal of anaesthesiology
  45. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment.2021Infectious diseases now
  46. Epstein-Barr virus infection is an important cause of hemophagocytic lymphohistiocytosis during chemotherapy for lymphoma.2021Infectious diseases now
  47. Hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patient.2021Infectious diseases now
  48. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.2021International immunopharmacology
  49. Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected.2021Leukemia & lymphoma
  50. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.2021Leukemia & lymphoma
  51. Epidemiological investigation of hemophagocytic lymphohistiocytosis in China.2021Orphanet journal of rare diseasesFree full text
  52. Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection.2021PLoS neglected tropical diseasesFree full text
Chinese-language papers (not in the count)8
  1. [Clinical Characteristics Analysis of EBV-associated Hemophagocytic Lymphohistiocytosis Patients with Acute Kidney Injury].2024Zhongguo shi yan xue ye xue za zhi
  2. [Clinical and genetic mutation characteristics of patients with primary hemophagocytic lymphohistiocytosis and their impact on prognosis].2024Zhonghua yi xue za zhi
  3. [Characteristic and prognosis of patients with non-EBV infection-associated hemophagocytic lymphohistiocytosis].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Evaluation of CD107a and perforin expression detection in the diagnosis of primary hemophagocytic lymphohistiocytosis].2022Zhonghua yi xue za zhi
  5. [New era of accurate diagnosis of hemophagocytic lymphohistiocytosis].2022Zhonghua yi xue za zhi
  6. [Interpretation of Chinese expert consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with lymphoma (2022)].2022Zhonghua yi xue za zhi
  7. [Exhaustion of CD8+T Lymphocytes Plays a Critical Role in the Pathogenesis of Secondary Hemophagocytic Lymphohistiocytosis].2021Zhongguo shi yan xue ye xue za zhi
  8. [Clinical study on the effect of etoposide-containing induction regimen for adult-onset Still's disease associated hemophagocytic syndrome].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status29
  1. Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingNCT07339345Lead sponsorPhase 2/Phase 3Start 2025-06
  2. Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant InfectionsNot yet recruitingNCT05988177Lead sponsorN/AStart 2023-08
  3. Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal InvolvementNot yet recruitingNCT06131489Lead sponsorStart 2023-12
  4. A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCTStatus unknownNCT06491719Lead sponsorN/AStart 2024-07
  5. Response Prediction in EBV-HLH Using Metabonomics AnalysisStatus unknownNCT05677178Lead sponsorStart 2023-01
  6. L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLHCompletedNCT05775705Lead sponsorN/AStart 2023-08
  7. Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLHStatus unknownNCT05546060Lead sponsorPhase 1Start 2022-07
  8. L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLHStatus unknownNCT05315336Lead sponsorPhase 3Start 2022-06
  9. Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH PatientsStatus unknownNCT05841342Lead sponsorStart 2022-10
  10. Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLHCompletedNCT05600959Lead sponsorStart 2022-11
  11. Zanubrutinib for HLHCompletedNCT05320575Lead sponsorPhase 3Start 2022-02
  12. Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCTStatus unknownNCT05532826Lead sponsorN/AStart 2022-10
  13. Rituximab Monotherapy for EBV-HLH and CAEBVStatus unknownNCT05384743Lead sponsorPhase 3Start 2022-02
  14. PD-1 Antibody Improve Mixed ChimerismStatus unknownNCT04944511Lead sponsorN/AStart 2021-07
  15. Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLHStatus unknownNCT05137522Lead sponsorN/AStart 2021-07
  16. DEP Combine With PD-1 Antibody as an Treatment for EBV-HLHStatus unknownNCT05164978Lead sponsorN/AStart 2021-05
  17. PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBVStatus unknownNCT04084626Lead sponsorPhase 3Start 2019-09
  18. Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.Status unknownNCT04077905Lead sponsorPhase 3Start 2019-08
  19. Ruxolitinib as a Salvage Therapy for Hemophagocytic LymphohistiocytosisStatus unknownNCT04120090Lead sponsorPhase 3Start 2019-07
  20. DEP-Ru Regimen as a Salvage Therapy for HLHStatus unknownNCT03533790Lead sponsorPhase 3Start 2018-06
  21. Etoposide in the First-line Treatment of Adult EBV-HLHStatus unknownNCT03742115Lead sponsorPhase 3Start 2018-12
  22. L-DEP as an Initial Treatment for EBV-HLHStatus unknownNCT02912702Lead sponsorPhase 3Start 2016-09
  23. Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown EtiologyStatus unknownNCT02862054Lead sponsorPhase 2/Phase 3Start 2015-01
  24. L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic LymphohistiocytosisStatus unknownNCT02631109Lead sponsorPhase 3Start 2015-12
  25. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
  26. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04
  27. Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedNCT05001737Study sitePhase 3Start 2021-12
  28. Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic SyndromeStatus unknownNCT04500886Study siteN/AStart 2020-08
  29. A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)Status unknownNCT04326348Study sitePhase 1Start 2020-07
More papers found outside PubMed (not counted)8
  1. Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability2025Bloodconference-abstract
  2. Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis2025Bloodconference-abstract
  3. CXCL-9 and IL-18: Potential Biomarkers for Efficacy Evaluation in Refractory Hemophagocytic Lymphohistiocytosis Treated with RED (Ruxolitinib, Emapalumab and Dexamethasone)2024Bloodconference-abstract
  4. Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study2024Bloodconference-abstract
  5. Zanubrutinib As Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis in Adults: A Single Center, Prospective Study2024Bloodconference-abstract
  6. Caebv Disease Originates from Infected Hematopoietic Stem Cells2023Bloodconference-abstract
  7. Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society2023Bloodconference-abstract
  8. P9.40: Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis Associated Acute Liver Failure: A Case Report2022Transplantationconference-abstract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 12 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.9%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 3320242025: 552025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07061938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesTreatment & relapseDiagnosis & look-alikesHead, eye socket & salivary glands
Departments in papersRheumatology & immunologyGastroenterology / hepatologyOphthalmology / neuro-ophthalmology
Papers it led12
  1. Does adjunctive endoscopic biliary drainage improve outcomes beyond glucocorticoids alone in IgG4-related pancreatobiliary disease?2025BMC gastroenterologyFree full text
  2. Correlations between IgG4-related disease and allergic reactions: implications for future therapeutic strategies.2025Clinical and experimental rheumatology
  3. Animal models of IgG4-related disease.2025Clinical immunology (Orlando, Fla.)
  4. Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.2025Clinical rheumatology
  5. Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.2025Rheumatology (Oxford, England)
  6. Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.2024Clinical rheumatology
  7. Performance of the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease in a Large Chinese Cohort.2024Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  8. Three cases of IgG4-RD complicated by splenic artery aneurysm: a complication of IgG4-RD?2024RMD openFree full text
  9. Association Between Immunoglobulin G4-Related Ophthalmic Disease and Nonlymphoid Malignancy Case Series and Comprehensive Review of the Literature.2023Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology SocietyFree full text
  10. Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.2022Clinical and experimental rheumatology
  11. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.2022Orphanet journal of rare diseasesFree full text
  12. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.2022Rheumatology (Oxford, England)
All its trials on ClinicalTrials.gov, any status2
  1. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseRecruitingNCT07061938Study sitePhase 1/Phase 2Start 2026-01
  2. Withdraw Drug in Stable IgG4-Related DiseaseStatus unknownNCT04124861Study siteN/AStart 2020-06
More papers found outside PubMed (not counted)1
  1. Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity2022Rheumatology & autoimmunityarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEye-only (ocular) myasthenia
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 4 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 2.0%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

3 hospitals in Beijing for Wilson disease28 hospitals in China for Wilson disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    China Registry for Genetic / Metabolic Liver Diseases
    Phase
    Not given
    Started
    2015-06
    Registry
    NCT03131427

    Age not stated (registered criteria)

    Led by Beijing Friendship Hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07465718

    Age 8 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsLiver disease & transplant
Departments in papersGastroenterology / hepatology
Papers it led4
  1. Dysfunction of ATP7B Splicing Variant Caused by Enhanced Interaction With COMMD1 in Wilson Disease.2025Cellular and molecular gastroenterology and hepatologyFree full text
  2. Hepatic progenitor cells reprogrammed from mouse fibroblasts repopulate hepatocytes in Wilson's disease mice.2025Stem cell research & therapyFree full text
  3. Laboratory and clinical evaluation of a microarray for the detection of ATP7B mutations in Wilson disease in China.2022Journal of clinical laboratory analysisFree full text
  4. Identification of potential modifier genes in Chinese patients with Wilson disease.2022Metallomics : integrated biometal scienceFree full text
Chinese-language papers (not in the count)3
  1. [Progress in drug therapy of Wilson's disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Reappraisal on the clinical diagnosis and treatment of hereditary liver diseases].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Construction and analysis of transcriptome-based hepatolenticular degeneration regulatory network].2022Sheng wu gong cheng xue bao = Chinese journal of biotechnology
All its trials on ClinicalTrials.gov, any status2
  1. China Registry for Genetic / Metabolic Liver DiseasesRecruitingNCT03131427Lead sponsorStart 2015-06
  2. Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.RecruitingNCT07465718Study sitePhase 3Start 2026-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 4 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 1.9%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

3 hospitals in Beijing for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLiver transplantComplications after surgeryDisease mechanisms
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led1
  1. Integrated Analysis of Intersecting Neutrophil Signatures in Behçet's Disease and Inflammatory Bowel Disease.2025International journal of rheumatic diseases
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 2 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 6.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led2
  1. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis.2023Journal of pediatric hematology/oncology
  2. Update of treatment for Gaucher disease.2022European journal of pharmacology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 12 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 4.0%.

Papers led
12
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 1120232024: 2220242025: 332025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    PBC Long-term Outcomes Study
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT07149675

    Age not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  2. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  3. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led12
  1. Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.2026Hepatology international
  2. Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice.2025BMC medicine
  3. GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.2025Journal of digestive diseases
  4. Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.2025The American journal of surgical pathology
  5. Primary Biliary Cholangitis Associated with Ulcerative Colitis: Case Series and Literature Review.2024Medicina (Kaunas, Lithuania)
  6. Obliteration of portal venules contributes to portal hypertension in biliary cirrhosis.2024The Journal of pathology
  7. Concomitant gallstone disease was not associated with long-term outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis.2023Journal of digestive diseases
  8. Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  9. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.2022Hepatology international
  10. Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.2022Hepatology international
  11. Rare liver diseases are not rare in China.2022Liver international : official journal of the International Association for the Study of the Liver
  12. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.2021Journal of gastroenterology and hepatology
Chinese-language papers (not in the count)3
  1. [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Clinical features and long-term prognosis of primary biliary cholangitis in patients with past hepatitis B virus infection].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. [Recommendations of APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Earlier papers (2016–2020)10
  1. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.2019Hepatology international
  2. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.2019Journal of gastroenterology and hepatology
  3. Alteration of liver-infiltrated and peripheral blood double-negative T-cells in primary biliary cholangitis.2019Liver international : official journal of the International Association for the Study of the Liver
  4. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.2018Revista espanola de enfermedades digestivas
  5. A brief review on prognostic models of primary biliary cholangitis.2017Hepatology international
  6. [Risk factors and therapeutic strategies for primary biliary cholangitis patients with poor prognosis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  7. [Research advances in primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  8. Optimal Adaptive Statistical Iterative Reconstruction Percentage in Dual-energy Monochromatic CT Portal Venography.2016Academic radiology
  9. Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis.2016European review for medical and pharmacological sciences
  10. Dual Energy CT (DECT) Monochromatic Imaging: Added Value of Adaptive Statistical Iterative Reconstructions (ASIR) in Portal Venography.2016PloS one
All its trials on ClinicalTrials.gov, any status8
  1. PBC Long-term Outcomes StudyRecruitingNCT07149675Lead sponsorStart 2025-05
  2. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Lead sponsorPhase 3Start 2009-09
  3. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  4. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  5. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  6. Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary CholangitisCompletedNCT05190523Study sitePhase 2Start 2022-04
  7. Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary CholangitisCompletedNCT05450887Study sitePhase 3Start 2021-09
  8. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisActive, not recruitingNCT05050136Study sitePhase 2Start 2021-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 4 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 4.0%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京友谊医院

Beijing Friendship Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Capital Medical University Affiliated Beijing Friendship Hospital; Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital of Capital Medical University; Beijing friendship hospital; Beijing Friendship Hospital Cancer Center; Beijing Friendship Hospita; Library of Beijing Friendship Hospital; Beijing Friendship Hospital of the Capital Medical University

Suggest a correctionDownload the data